Health economics and RSV.
Paediatr Respir Rev
; 10 Suppl 1: 12-3, 2009 Jun.
Article
en En
| MEDLINE
| ID: mdl-19651392
ABSTRACT
An economic analysis was performed in Spain to evaluate the efficiency (cost-effectiveness) of palivizumab in preventing severe RSV infection in premature infants with GA 32-35 and two or more risk factors (RF). The design was a decision tree model using data from the scientific literature and the FLIP I and FLIP II studies IRIS Study Group. The main effectiveness measure was quality-adjusted life years (QALY) gained from both the National Health System (NHS) and societal perspectives. Prophylaxis with palivizumab was found to produce an incremental cost-effectiveness ratio (ICER) of 13,849euro/QALY from the NHS perspective, and 4,605euro/QALY from the societal perspective. Palivizumab is a cost-effective therapy as prophylaxis against RSV in infants with GA 32-35 and two or more RF. Its use is efficient from the NHS perspective, since the cost of a QALY, even in the least favourable scenarios, is lower than the threshold of 30,000euro/QALY considered socially acceptable in Europe.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Virus Sincitiales Respiratorios
/
Costos de la Atención en Salud
/
Infecciones por Virus Sincitial Respiratorio
/
Anticuerpos Monoclonales
Tipo de estudio:
Health_economic_evaluation
/
Prognostic_studies
/
Risk_factors_studies
Aspecto:
Patient_preference
Límite:
Humans
/
Newborn
País/Región como asunto:
Europa
Idioma:
En
Revista:
Paediatr Respir Rev
Asunto de la revista:
PEDIATRIA
Año:
2009
Tipo del documento:
Article
País de afiliación:
España